Richard Morris

Richard Morris joined Carisma Therapeutics in June 2021 bringing more than 25 years of experience in building and growing successful biotech organizations with a track record of delivering corporate value through capital fundraising (including IPOs), financial strategy and operations execution, and business development efforts.

Mr. Morris previously served as the CFO at Passage Bio, where he was instrumental in transforming the genetic medicines company from a private start-up to a public development stage company. Before that, he was the Executive Vice President and CFO for Context Therapeutics; he also was CFO for Vitae Pharmaceuticals, acquired by Allergan in 2016, and held several senior financial roles at ViroPharma, acquired by Shire in 2013.

Richard holds a BS in Accounting from Saint Joseph’s University and is a certified public accountant.